Join the Nivolumab group to help and get support from people like you.
Nivolumab News
Neoadjuvant Nivolumab, Ipilimumab Safe for dMMR Colon Cancer
WEDNESDAY, June 5, 2024 – Neoadjuvant nivolumab plus ipilimumab has an acceptable safety profile in patients with locally advanced mismatch repair-deficient (dMMR) colon cancer, according to a study...
ASCO: Neoadjuvant Ipilimumab + Nivolumab Ups Survival in Resectable Melanoma
WEDNESDAY, June 5, 2024 – Neoadjuvant ipilimumab plus nivolumab followed by surgery results in longer event-free survival than surgery followed by adjuvant nivolumab among patients with resectable,...
Perioperative Nivolumab Tops Chemo for Survival in Resectable Lung Cancer
FRIDAY, May 17, 2024 – For patients with resectable non-small cell lung cancer (NSCLC), perioperative treatment with nivolumab results in significantly longer event-free survival, according to a...
U.S. Food and Drug Administration Approves Opdivo (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
PRINCETON, N.J.--(BUSINESS WIRE) Mar 07, 2024 – Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo® (nivolumab), in combination with ...
Injected Opdivo for Kidney Cancer Works Equally Well as IV Form: Study
TUESDAY, Jan. 30, 2024 – Opdivo, one of the new generation of immunotherapy cancer treatments, appears to help kidney cancer patients equally well when given as a quick injection versus the current...
FDA Approves Nivolumab as Adjuvant Treatment for Melanoma
WEDNESDAY, Oct. 18, 2023 – The U.S. Food and Drug Administration has approved Opdivo (nivolumab) for the adjuvant treatment of completely resected stage IIB/C melanoma in patients ages 12 years and...
U.S. Food and Drug Administration Approves Opdivo (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma
In the Phase 3 CheckMate -76K trial, Opdivo demonstrated a statistically significant improvement in recurrence-free survival compared to placebo1 CheckMate -76K marks the fifth Opdivo-based...
Gemcitabine, Cisplatin, Nivolumab Facilitate Bladder Sparing
WEDNESDAY, Oct. 4, 2023 – For patients with muscle-invasive bladder cancer (MIBC), treatment with gemcitabine, cisplatin, plus nivolumab facilitates bladder sparing, according to a study published...
Immune Checkpoint Inhibitors Can Be Active in Penile Cancer
WEDNESDAY, Aug. 23, 2023 – Immune checkpoint inhibitors (ICIs) are active in some patients with penile cancer (PeCa), according to a study published online Aug. 11 in the Journal of the National...
Nivolumab + Ipilimumab Tops Ipilimumab Alone in Metastatic Melanoma
WEDNESDAY, Aug. 23, 2023 – For patients with metastatic melanoma who receive frontline anti-programmed death protein 1 (PD-1) or therapy against programmed cell death 1 ligand 1 and whose tumors...
T-Cell Tolerant Fraction Can Predict Immunotherapy Toxicity
MONDAY, Aug. 21, 2023 – The T-cell tolerant fraction predicts clinically significant immune-related adverse events (irAEs) among patients with cancer treated with immune checkpoint inhibitors...
A New Treatment Option for a Form of Sudden Hair Loss
THURSDAY, Aug. 17, 2023 – A new type of medication, JAK inhibitors, can effectively treat moderate to severe alopecia areata, a hair loss condition that has been historically hard to treat. A study...
Immune-Based Cancer Drugs Offer Hope Against Penile Cancers
TUESDAY, Aug. 15, 2023 – Men who have a rare cancer of the penis may have a new treatment option, according to researchers who found promise in immunotherapy. This new study focused on cancer that...
U.S. Food and Drug Administration Approves Two Opdivo (nivolumab)-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Opdivo in combination with chemotherapy and Opdivo plus Yervoy® (ipilimumab) approved based on a Phase 3 trial showing improved overall survival versus chemotherapy alone1,2 Opdivo-based ...
FDA Approves Opdualag (nivolumab and relatlimab-rmbw) for the Treatment of Patients with Unresectable or Metastatic Melanoma
PRINCETON, N.J.--(BUSINESS WIRE)-- March 18, 2022 – Bristol Myers Squibb (NYSE: BMY) today announced that Opdualag (nivolumab and relatlimab-rmbw),anew, first-in-class,fixed-dose combination of...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Hepatocellular Carcinoma, Colorectal Cancer, Melanoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma